单位:[1]National Integrated Traditional and Western Medicine Center for Cardivascular Disease, China-Japan Friendship Hospital, Beijing 100101, China[2]Department of Psychiatric-Neuroimaging-Genetics and Morbidity Laboratory (PNGC-Lab), Nankai University Affiliated Anding Hospital, Tianjin Mental Health Center, Mental Health Teaching Hospital, Tianjin Medical University, Tianjin 300222, China[3]Department of Psychiatry, Wenzhou Seventh People's Hospital, Wenzhou 325000, China[4]Department of Psychiatry, School of Mental Health, Psychiatric Genetics Laboratory (PSYG-Lab), Jining Medical University, Jining 272191, China[5]Department of China, Canada Biological Psychiatry Lab, Xiamen Xianyue Hospital, Xiamen 361000, China[6]Department of Psychiatry, College of Basic Medical Research, Tianjin Medical University, Tianjin 300000, China
Patients with schizophrenia have a higher incidence of coronary artery disease. This meta-analysis was performed to evaluate the influence of a prior diagnosis of schizophrenia on mortality following acute coronary syndrome (ACS). Relevant longitudinal follow-up studies were obtained via systematic search of PubMed and Embase databases. A random effect model was used to perform the meta-analysis. This meta-analysis included 3,611,343 hospitalized patients with ACS from nine follow-up studies. The results show that, in patients with schizophrenia, ACS was associated with a significantly higher risk of mortality (multivariate adjusted risk ratio [RR]: 1.66, p < .001) with significant heterogeneity (I2 = 93%) compared to the results of mentally healthy patients. Subgroup analyses demonstrated that patients with schizophrenia were associated with higher ACS mortality within one month (RR: 1.68, p < .001) and during a follow-up period of >= one year (RR: 1.71, p = .01), in studies with (RR: 1.65, p = .06) and without the adjustment of revascularization treatments (RR: 1.68, p = .004), as compared with the results of mentally healthy patients. These results indicate that patients with schizophrenia have a higher than expected mortality risk in the case of acute coronary events.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81871052]; Key Projects of Natural Science Foundation of Tianjin, China [17JCZDJC35700]; Tianjin Health Bureau Foundation [2014KR02]; Wenzhou Science and Technology Project [ZS2017011]
第一作者单位:[1]National Integrated Traditional and Western Medicine Center for Cardivascular Disease, China-Japan Friendship Hospital, Beijing 100101, China
通讯作者:
通讯机构:[2]Department of Psychiatric-Neuroimaging-Genetics and Morbidity Laboratory (PNGC-Lab), Nankai University Affiliated Anding Hospital, Tianjin Mental Health Center, Mental Health Teaching Hospital, Tianjin Medical University, Tianjin 300222, China[3]Department of Psychiatry, Wenzhou Seventh People's Hospital, Wenzhou 325000, China[4]Department of Psychiatry, School of Mental Health, Psychiatric Genetics Laboratory (PSYG-Lab), Jining Medical University, Jining 272191, China[5]Department of China, Canada Biological Psychiatry Lab, Xiamen Xianyue Hospital, Xiamen 361000, China[6]Department of Psychiatry, College of Basic Medical Research, Tianjin Medical University, Tianjin 300000, China[*1]Department of Psychiatry, College of Basic Medical Research, Tianjin Medical University, No. 22, Qixiangtai Road, Heping District, Tianjin, 300070, China.
推荐引用方式(GB/T 7714):
Shao Mingjing,Tian Hongjun,Wang Lina,et al.Mortality risk following acute coronary syndrome among patients with schizophrenia: A meta-analysis[J].PROGRESS in NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY.2020,96:doi:10.1016/j.pnpbp.2019.109737.
APA:
Shao, Mingjing,Tian, Hongjun,Wang, Lina,Jiang, Deguo,Ji, Feng&Zhuo, Chuanjun.(2020).Mortality risk following acute coronary syndrome among patients with schizophrenia: A meta-analysis.PROGRESS in NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY,96,
MLA:
Shao, Mingjing,et al."Mortality risk following acute coronary syndrome among patients with schizophrenia: A meta-analysis".PROGRESS in NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY 96.(2020)